CAMP4 Therapeutics Corp. (NASDAQ: CAMP) reported full‑year 2025 results on March 5, 2026. Cash and cash equivalents rose to $109.5 million from $64.0 million at the end of 2024, giving the company a runway that management expects to extend through 2028. Revenue for the year was $3.5 million, a modest increase over the $3.3 million reported in 2024, while the net loss widened to $80.4 million from $51.8 million in 2024. The larger loss was driven largely by a $29.8 million non‑cash charge related to a derivative tranche liability created by a private placement.
The company also closed a private placement that raised $50 million in gross proceeds, with the possibility of an additional $50 million, and completed an underwritten common‑stock offering that brought in $30 million. In addition, CAMP4 entered a collaboration with GlaxoSmithKline that provided a $17.5 million upfront payment and the potential for milestone payments and tiered royalties. The partnership focuses on using CAMP4’s RNA‑Actuating Platform to identify and develop antisense oligonucleotide therapeutics for neurodegenerative and kidney diseases.
On the pipeline front, GLP toxicology studies for the SYNGAP1 lead candidate CMP‑002 are ongoing, and the company expects to launch a global Phase 1/2 trial in the second half of 2026. Management also announced a pause in further investment in the CMP‑001 program and is exploring external partnerships to advance that asset.
CEO Josh Mandel‑Brehm emphasized that the financing and partnership give CAMP4 a strong financial foundation to pursue its most promising programs. He noted that the company’s focus on up‑regulating gene expression through its RAP technology positions it to address unmet needs in rare genetic disorders.
The derivative tranche liability, which stands at $44.8 million as of December 31, 2025, represents a potential dilution risk if the company’s share price falls below the strike price. Management highlighted that the net loss increase is largely attributable to the one‑time derivative charge, while R&D expenses fell slightly to $38.2 million from $38.8 million in 2024, and G&A expenses rose to $17.4 million from $14.9 million, reflecting increased professional costs.
With the new capital and the GSK collaboration, CAMP4 is positioned to fund its planned clinical activities and maintain a robust cash cushion for the next several years, while the company continues to refine its pipeline and explore additional partnership opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.